Male coping through a long-term cancer trajectory. Secondary outcomes from a RTC examining the effect of a multidisciplinary rehabilitation program (RePCa) among radiated men with prostate cancer

Figures & data

Figure 1. CONSORT-flow chart of a randomized study (RePCa) with follow-up in patients with prostate cancer.

Table 1. Sociodemographic and biological pre-intervention characteristics of 161 participants and 48 non-participants with primary prostate cancer included in a randomized controlled trial after radiotherapy and androgen deprivation therapy, 2010–2012, Denmark.

Sociodemographic characteristics	Intervention group (n = 79)	Control group (n = 82)	Non-participants (n = 48)
Age at first radiotherapy date (years) mean (SD):	68.2 (4.8)	69.0 (5.2)	68.7 (6.4)
Weight (kg) reported at pre-intervention mean (SD)	84.7 (12.7)	86.3 (14.8)	85.9 (15.6)
Unknown	1	3	7
Body mass index (BMI) kg/m^2 mean (SD)	27.1 (3.6)	27.4 (4.1)	27.2 (4.6)
Unknown	1	3	7
Social status reported at pre-intervention
Living alone	10 (13%)	12 (15%)	8 (19%)
Living with a spouse	68 (87%)	67 (85%)	33 (81%)
Unknown	1	3	7
Education:
Basic (10 years or less)	31 (40%)	36 (46%)	21 (52%)
Youth (high school)	24 (31%)	23 (29%)	12 (30%)
Medium (profession)	18 (23%)	18 (23%)	6 (15%)
Higher (university)	5 (6%)	2 (2%)	1 (3%)
Unknown	1	3	8
Smoking status at pre-intervention
Never smoker	33 (42%)	32 (41%)	12 (29%)
Past smoker	30 (39%)	35 (44%)	20 (49%)
Current smoker	15 (19%)	12 (15%)	9 (22%)
Unknown	1	3	7
Medical characteristics
PSA pretreatment serum mean ng/ml (SD)	21.5 (17.7)	19.8 (16.8)	21.6 (18.4)
Gleason score
<7	10 (13%)	17 (21%)	10 (21%)
7	47 (59%)	44 (54%)	25 (52%)
>7	22 (28%)	21 (25%)	13 (27%)
Tumor stage
T1	8 (10%)	9 (11%)	6 (12%)
T2	34 (44%)	35 (43%)	23 (48%)
T3	36 (46%)	38 (46%)	19 (40%)
Unknown	1
D’Amico risk groups
Low	1 (1%)	3 (4%)	6 (12%)^a
Intermediate	19 (24%)	13 (16%)	8 (17%)
High	59 (75%)	65 (80%)	34 (71%)
Unknown		1
Hormone therapy
No	3 (4%)	2 (3%)	5 (11%)^b
Androgen deprivation therapy (ADT)	76 (96%)	79 (97%)	42 (89%)
Unknown		1	1
Patient-reported comorbidity at pre-intervention
Charlson Comorbidity Indexc
Score 1	20 (25%)	19 (23%)	13 (27%)
Score 2	4 (5%)	5(6%)	1 (2%)
Score 3	0	0	0
Score 6	0	0	0

^a Fisher’s exact p = 0.028; ^bFisher’s exact p = 0.049; ^cThe Charlson Comorbidity Index predicts the one-year mortality for a patient who may have a range of comorbid conditions, such as heart disease, AIDS or cancer (a total of 22 conditions). Each condition is assigned a score of 1, 2, 3 or 6, depending on the risk of dying associated with each one. In the study the scores are found by record audit.

Table 2. Scores of mental adjustment styles pre-radiation, post-radiation, and post-intervention 6 months and 3 years after radiotherapy.

	Intervention group				Control group
	Mean (95% CI)				Mean (95% CI)
Mini-MAC Mean (95% CI)	Pre-radiation n = 75	Post-radiation baseline n = 77	Post-intervention n = 76	3-yearfollow-up n = 71	Pre-radiation n = 79	Post-radiation baseline n = 76	Post-intervention n = 73	3-yearfollow-up n = 67	p^a	p^b
Fighting Spirit	12.0 (11.4;12.6)	12.1 (11.6;12.6)	12.1 (11.5;12.6)	11.1 (10.4;11.8)	12.2 (11.6;12.7)	12.2 (11.6;12.8)	11.6 (11.0;12;2)	11.3 (10.5;12.1)	0.025*	0.585
Fatalism	12.7 (12.1;13.3)	12.5 (11.9;13.1)	12.3 (11.7;13.0)	11.8 (11.1;12.5)	12.5 (11.9;13.1)	12.3 (11.7;12.9)	12.2 (11.6;12.8)	12.0 (11.2;12.7)	0.991	0.841
Cognitive Avoidance	9.9 (9.3;10.5)	9.6 (9.0;10.3)	9.7 (9.0;10.3)	9.3 (8.6;10.1)	9.8 (9.2;10.4)	9.7 (9.0;10.5)	9.8 (9.0;10.5)	10.4 (9.5;11.3)	0.853	0.044*
Anxious Preoccupation	16.6 (15.4;17.7)	15.4 (14.3;16.6)	14.8 (13.9;15.7)	14.5 (13.4;15.6)	15.6 (14.7;16.6)	14.5 (13.4;15.5)	14.2 (13.1;15.3)	13.6 (12.2;14.9)	0.841	0.733
Helplessness/Hope-lessness	11.1 (10.4;11.8)	10.9 (10.2;11.7)	10.3 (9.6;10.9)	10.8 (10.0;11.7)	11.2 (10.4;11.9)	10.5 (9.7;11.3)	10.7 (10.0;11.5)	10.7 (9.7;11.6)	0.076	0.763

^a Numbers refer to the p-value between groups at post-intervention (6 month) in a linear regression model adjusted for baseline score (post-radiation); ^bNumbers refer to the p-value between groups at 3-year follow-up in a linear regression model adjusted for baseline score (post-radiation), and for the post-intervention score. Reported p-values are two-sided, and p < 0.05 considered statistically significant*.

Figure 2. Percent of self-reported moderate-severe depression at different timepoints in a randomized study with Danish prostate cancer patients.